

Myocardial Ischemia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M82BC83BA47EN.html>

Date: February 2020

Pages: 88

Price: US\$ 2,000.00 (Single User License)

ID: M82BC83BA47EN

Abstracts

Myocardial Ischemia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2020, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players

involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Myocardial Ischemia - Overview
- Myocardial Ischemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myocardial Ischemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myocardial Ischemia - Companies Involved in Therapeutics Development
- Angionetics Inc
- AstraZeneca Plc
- Bayer AG
- Cadrock Pty Ltd
- Caladrius Biosciences Inc
- Cellmid Ltd
- Chrysalis BioTherapeutics Inc
- CohBar Inc
- Everon Biosciences Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- Lixte Biotechnology Holdings Inc
- NoNO Inc
- Omniox Inc
- Q BioMed Inc
- Symvivo Inc
- Vasade Biosciences Inc
- Myocardial Ischemia - Drug Profiles
- alferminogene tadenovec - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AZD-8601 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
azithromycin + doxycycline + rifabutin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

OMX-4.80P - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rusalotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular
and Central nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Ischemia - Dormant Projects

Myocardial Ischemia - Discontinued Products

Myocardial Ischemia - Product Development Milestones

Featured News & Press Releases

Feb 20, 2019: Phase 1 data published in Nature Communications show potential of
mRNA encoding VEGF-A as a regenerative therapeutic

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on
Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart
Disease

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study

Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition

Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2020
Myocardial Ischemia - Pipeline by AstraZeneca Plc, H1 2020
Myocardial Ischemia - Pipeline by Bayer AG, H1 2020
Myocardial Ischemia - Pipeline by Cadrock Pty Ltd, H1 2020
Myocardial Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2020
Myocardial Ischemia - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Myocardial Ischemia - Pipeline by CohBar Inc, H1 2020
Myocardial Ischemia - Pipeline by Everon Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
Myocardial Ischemia - Pipeline by NoNO Inc, H1 2020
Myocardial Ischemia - Pipeline by Omniox Inc, H1 2020
Myocardial Ischemia - Pipeline by Q BioMed Inc, H1 2020
Myocardial Ischemia - Pipeline by Symvivo Inc, H1 2020
Myocardial Ischemia - Pipeline by Vasade Biosciences Inc, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Myocardial Ischemia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Angionetics Inc
AstraZeneca Plc
Bayer AG
Cadrock Pty Ltd
Caladrius Biosciences Inc
Cellmid Ltd
Chrysalis BioTherapeutics Inc
CohBar Inc
Everon Biosciences Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Lixte Biotechnology Holdings Inc
NoNO Inc
OmniOX Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc

I would like to order

Product name: Myocardial Ischemia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M82BC83BA47EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M82BC83BA47EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970